In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vernalis Group PLC

Division of Ligand Pharmaceuticals Inc.

Latest From Vernalis Group PLC

European IPOs Hold Their Own

The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists. The wisdom's changed (or some of it, anyway).

BioPharmaceutical Europe

Europe's Flavors of Sustainable BioPharma

Europe's financing environment makes it difficult to build big biotech from scratch. But sustainable biopharma firms are nevertheless emerging--mostly through the transformation of existing pharma assets.

BioPharmaceutical Europe

Celltech-UCB: UK's Loss Could be Mid-Sized Pharma's Gain

Celltech's shareholders should be delighted with the price of UCB's acquisition, since the company probably could not have otherwise secured the kind of alliance it wanted for its flagship product. But UK biotech has sustained a severe blow, losing its only truly liquid biotech. Meanwhile, in suggesting that late-stage deal prices may be reaching their upper limits, the deal sends a wake-up call to other mid-sized European pharma. It's time to leverage shareholder, cash and size differences with Big Pharma to recast Euro-focused primary-care operations into higher profit, albeit higher risk, specialist businesses.

BioPharmaceutical Europe

A Rare Second Chance at Partnering Success for Vernalis' Underperforming Frova

Vernalis has bought back rights to its Frova migraine treatment in North America from Elan, agreeing to pay $55 million over the next two years. Frova, sold there by Elan and UCB, had failed to reach even the most modest sales expectations. Now Vernalis plans to re-partner the drug, hoping a label-extension to menstrual-associated migraine lands it significantly better terms than its original 1998 deal with Elan. But Vernalis needs to raise money to complete the buyout, and the dynamics of the US migraine market suggest that until it can differentiate the drug on the basis of the MAM label, a huge primary care sales force would be necessary to gain a respectable share of the market.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Vanguard Medica Group PLC
  • Vernalis Group PLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Ligand Pharmaceuticals Inc.
  • Senior Management
  • Peter Worrall, CEO
    Colin T Dourish, SVP, Research
  • Contact Info
  • Vernalis Group PLC
    Phone: (44) 118 977 3133
    Oakdene Ct. 613 Reading Rd.
    Winnersh, RG41 5UA